AVTX (Avalo Therapeutics, Inc.) Net Profit

AVTX (Avalo Therapeutics) - company brandmark

Avalo Therapeutics, Inc (AVTX) develops medications to combat rare immune pathologies. Profit potential is based on exclusive patents that allow the company to exercise pricing power over therapy costs. The price action (separate_profit) reflects profit dynamics, which currently stand at -0.10. Business stability is ensured by a loyal staff of scientists and the active recruitment of clinical trial experts, which prevents the leakage of intellectual capital.

AVTX (Avalo Therapeutics, Inc) Net Profit history from 07/04/2022 to 11/01/2026

Analytical breakdowns and data insights for company Avalo Therapeutics (AVTX)

- price and consensus price forecast:
Stock Quotes Avalo Therapeutics Inc|AVTX - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Avalo Therapeutics Inc|AVTX - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share Avalo Therapeutics|AVTX - Book Capitalization|Market Capitalization to Book Value avalotx.com|AVTX - Aggregate Company Assets
- debt and solvency information:
Total Debt to Equity Ratio Avalo Therapeutics, Inc|AVTX - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Avalo Therapeutics, Inc.|AVTX - Company Total Debt|Debts to Book Capitalization Avalo Therapeutics Inc|AVTX - Company Long-Term Debt|Company Short-Term Indebtedness Avalo Therapeutics|Immediate Liquidity avalotx.com
- net income and valuation multiples indicators:
AVTX - Net Profit
Summary company analysis:Avalo Therapeutics, Inc
Core merchandise of Avalo Therapeutics Inc.

Avalo Therapeutics, Inc (AVTX) focuses on high-cost clinical trials for inflammatory pathologies. This indicator captures daily net profit, smoothing out short-term market noise to identify the long-term trend. Analyzing the company's profit allows for an assessment of the actual financial result after deducting all operating expenses. Given fixed R&D costs and a lack of marginal scalability, line volatility signals risks. Stable growth would confirm capital resilience.

Main competitors

Net Income argenx BVBA|BNTX (BioNTech SE) - Net Profit|Net Profit Abivax Pharma|Net Income ADMA (ADMA Biologics, Inc.)|PTGX (Protagonist Therapeutics, Inc.) - Final Profit|Net Profit IMVT (Immunovant Corp)|Net Financial Result Kiniksa Corp (KNSA)|GRFS - Company Net Income|adaptivebiotech.com (ADPT) - Net Income|Celldex Therapeutics, Inc. (CLDX) - Company Net Income|Net Income Aurinia Pharmaceuticals Inc|Net Income BCRX|Net Profit Vera Corp|Company Net Income Dianthus Therapeutics (DNTH)|pharvaris.com - Company Profit|Net Profit ABCL (AbCellera Biologics Inc)|Tourmaline Bio Inc (TRML) - Company Net Income|Intrexon - Net Profit|PHAR - Net Profit|NKTR (Nektar Therapeutics) - Net Income|UPB (upstreambio.com) - Company Net Income|ZBIO (Zenas Biopharma) - Net Profit|Net Profit Immunome Inc|Company Net Income Gossamer Corp (GOSS)|Company Net Income KALV (KalVista Corp)|Company Net Income Septerna Inc SEPN|pieris.com (PVLA) - Company Net Income|SVRA: Net Income|Final Profit RIGL (Rigel Pharma)|ANAB (AnaptysBio Corp) - Net Income|ATXS: Profit After Payment of Taxes|ENGN (enGene Holdings Inc.) - Net Profit|RAPT: Final Profit|Net Profit JBIO|ACRS - Company Net Income|Company Net Income Kyverna KYTX|Final Profit TLSA|Cabaletta Bio, Inc. - Net Profit|VTYX - Net Profit|Theratechnologies (THTX) - Company Net Income|Profit After Tax ELDN (Eledon Pharmaceuticals Inc.)|AGEN (Agenus Inc) - Net Profit|Company Net Income Climb Bio, Inc CLYM|Net Income ZURA (Zura Bio Limited)|Net Profit atyrpharma.com (ATYR)|Adagene Inc. - Net Income|Profit After Payment of Taxes IMA (ImageneBio)|Shattuck Therapeutics - Net Profit|Net Financial Result Equillium, Inc. EQ|CNTB: Net Profit|Net Income Immunic|Company Net Income Atara Biotherapeutics, Inc.|InflaRx GmbH (IFRX) - Net Financial Result|Net Income XFOR (X4 Pharma)|ACET (adicetbio.com) - Final Profit|Net Profit CELU (Celularity)|Net Financial Result inmunebio.com (INMB)|BRNS - Company Net Income|KZR (Kezar Life Sciences Inc.) - Company Profit|SABS: Net Profit|Net Income Akari Therapeutics, Plc|ENLV (Enlivex Therapeutics Ltd) - Net Profit|Net Profit Q32 Bio Corp|Net Income GOVX (GeoVax)|Company Net Income EDSA (Edesa Biotech Inc)|iBio Corp - Net Income|Profit After Payment of Taxes CARM (Carisma Therapeutics Inc)|XTLB: Net Income|BOLT (Bolt Biotherapeutics) - Company Profit|hcwbiologics.com (HCWB) - Company Net Income|Profit After Tax APVO (Aptevo Therapeutics Inc.)|AIM (AIM ImmunoTech) - Net Profit|ADTX: Final Profit|Net Profit GRI|Net Profit xortx.com (XRTX)|Company Net Income Vyome Holdings HIND|Final Profit REVB|INDP - Company Net Income|BiondVax Pharmaceuticals (SCNI) - Net Income|CALI: Net Profit|Affimed N.V. (AFMD) - Net Profit|Net Income ALLK|HOOK: Final Profit|Net Profit IGMS|Net Financial Result iTeos Pharma|Company Net Income Ocean Biomedical, Inc. OCEA|TCBP - Net Income|THRD - Company Net Income